Nicholas H. Stillman

Nicholas H. Stillman

Auto-generated profile, based on publicly available information

Nicholas H. Stillman

Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences Prague Czech Republic

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
NSNicholas H. Stillman
Nicholas H. Stillman
JJJohnson A. Joseph
Johnson A. Joseph
JAJemil Ahmed
Jemil Ahmed
CBCharles Zuwu Baysah
Charles Zuwu Baysah
RDRyan A. Dohoney
Ryan A. Dohoney
SKSunil Kumar
Sunil Kumar
Abberent protein-protein interactions potentiate many diseases and one example is the toxic, self-assembly of α-Synuclein in the dopaminergic neurons of patients with Parkinson’s disease; therefore, a potential therapeutic strategy is the small molecule modulation of α-Synuclein aggregation. In this work, we develop an Oligopyridylamide based 2-dimensional Fragment-Assisted Structure-based Technique to identify antagonists of α-Synuclein aggregation. The technique utilizes a fragment-based screening of an extensive array of non-proteinogenic side chains in Oligopyridylamides, leading to the identification of NS132 as an antagonist of the multiple facets of α-Synuclein aggregation. We further identify a more cell permeable analog (NS163) without sacrificing activity. Oligopyridylamides rescue α-Synuclein aggregation mediated Parkinson’s disease phenotypes in dopaminergic neurons in early and post disease Caenorhabditis elegans models. We forsee tremendous potential in our technique to identify lead therapeutics for Parkinson’s disease and other diseases as it is expandable to other oligoamide scaffolds and a larger array of side chains.

11 March 2025 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
CBCharles Zuwu Baysah
Charles Zuwu Baysah
RDRyan A. Dohoney
Ryan A. Dohoney
LPL. Palanikumar
L. Palanikumar
NSNicholas H. Stillman
Nicholas H. Stillman
APAlexandra L. Penney
Alexandra L. Penney
SKSunil Kumar
Sunil Kumar

24 December 2024 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
EOEmily G. Oldani
Emily G. Oldani
NSNicholas H. Stillman
Nicholas H. Stillman
RDRyan A. Dohoney
Ryan A. Dohoney
CBCharles Zuwu Baysah
Charles Zuwu Baysah
SKSunil Kumar
Sunil Kumar

1 April 2026 in Science Translational Medicine
Verified
Journal Article
Closed access
RDRyan A. Dohoney
Ryan A. Dohoney
LPL. Palanikumar
L. Palanikumar
EOEmily Oldani
Emily Oldani
Jinfeng XingJinfeng Xing
Jinfeng Xing
JJJohnson A. Joseph
Johnson A. Joseph
SKSunil Kumar
Sunil Kumar
Synucleinopathies is an umbrella term for multiple neurological disorders, including Parkinson’s disease (PD), Lewy body dementia (LBD), and multiple system atrophy (MSA). A central pathological hallmark of synucleinopathies is the aggregation of α-synuclein (αS, a neuronal protein) and its prion-like spread. Therefore, inhibition of αS aggregation and spread is considered a viable therapeutic approach for the treatment of synucleinopathies. Foldamers are synthetic ligands that mimic the secondary structure of proteins. Using an oligoquinoline (OQ) scaffold–based foldamer approach, we have previously identified a foldamer (SK-129) that potently inhibits αS aggregation. Here, using a wide range of biophysical, cellular, and in vivo methods, we showed that SK-129 rescued synucleinopathy phenotypes in cellular, Caenorhabditis elegans , and human induced pluripotent stem cell (iPSC)–derived neuron models. SK-129 specifically bound to neurotoxic αS oligomers with ~6-fold higher affinity ( K d = 221 ± 29 nM) than to physiological αS monomer, validating αS oligomers as a therapeutic target. Furthermore, SK-129 efficiently crossed the blood-brain barrier (BBB) and exhibited favorable pharmaceutical properties in mice. Treatment with SK-129 prevented brain histopathology and increased survival in a mouse model expressing human A53T mutant αS without showing any apparent cytotoxicity. SK-129 inhibited αS aggregation mediated by exosomes derived from C. elegans or patients with PD in HEK293T reporter cells. SK-129 completely inhibited the coaggregation of αS-tau, a pathological biomarker for LBD in both cellular and mouse models. Overall, we report a potent foldamer with therapeutic potential for PD and LBD.

21 September 2026 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
PDF file
AKAlireza Abbasi Kejani
Alireza Abbasi Kejani
PDParitosh Dey
Paritosh Dey
NSNicholas H. Stillman
Nicholas H. Stillman
DADaniel M. Andrade
Daniel M. Andrade
MŠMichal Šimek
Michal Šimek
PPPaulo H. S. Paioti
Paulo H. S. Paioti
We report the first examples of catalytic, intramolecular N‐heterocycle arylation by nucleophilic aromatic substitution (S N Ar), a general method for synthesis of highly strained macrocycles and medium‐sized heterobiaryl atropisomeric rings. Key to the approach is the ability to generate a strong base catalytically, as the desired cyclizations can be problematic under non‐catalytic conditions. Substitution reactions catalyzed by Brønsted bases often suffer from poor turnover because leaving groups are poorly basic. We put forth a process in which base regeneration does not depend on p K a considerations, but on reaction of a fluoride catalyst (Lewis base) with an organosilane (base‐embedding electrophile). Our protocol is amenable to an unprecedented broad range of heterocycles and highly functionalized and sterically hindered fluoroarenes. Despite ring strain, direct formation of C─N stereogenic axis can be carried out with linear substrates unbiased for cyclization and with tryptophan‐containing peptides. We provide synthesis of drug‐like cyclic and atropisomeric molecules which are elusive in medicinal chemistry screenings, as well as a direct macrocyclization route toward stereochemically and structurally diverse atropopeptides, molecules inspired by bioactive and naturally occurring ribosomally synthesized post‐translationally modified peptides (RiPPs). This work establishes a unique disconnection toward cyclic heterobiaryl molecules and catalysis that is to unlock other transformations.

21 September 2026 in Angewandte Chemie
Verified
Journal Article
Open access
AKAlireza Abbasi Kejani
Alireza Abbasi Kejani
PDParitosh Dey
Paritosh Dey
NSNicholas H. Stillman
Nicholas H. Stillman
DADaniel M. Andrade
Daniel M. Andrade
MŠMichal Šimek
Michal Šimek
PPPaulo H. S. Paioti
Paulo H. S. Paioti
We report the first examples of catalytic, intramolecular N‐heterocycle arylation by nucleophilic aromatic substitution (S N Ar), a general method for synthesis of highly strained macrocycles and medium‐sized heterobiaryl atropisomeric rings. Key to the approach is the ability to generate a strong base catalytically, as the desired cyclizations can be problematic under non‐catalytic conditions. Substitution reactions catalyzed by Brønsted bases often suffer from poor turnover because leaving groups are poorly basic. We put forth a process in which base regeneration does not depend on p K a considerations, but on reaction of a fluoride catalyst (Lewis base) with an organosilane (base‐embedding electrophile). Our protocol is amenable to an unprecedented broad range of heterocycles and highly functionalized and sterically hindered fluoroarenes. Despite ring strain, direct formation of C─N stereogenic axis can be carried out with linear substrates unbiased for cyclization and with tryptophan‐containing peptides. We provide synthesis of drug‐like cyclic and atropisomeric molecules which are elusive in medicinal chemistry screenings, as well as a direct macrocyclization route toward stereochemically and structurally diverse atropopeptides, molecules inspired by bioactive and naturally occurring ribosomally synthesized post‐translationally modified peptides (RiPPs). This work establishes a unique disconnection toward cyclic heterobiaryl molecules and catalysis that is to unlock other transformations.